Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09 avr. 2024 16h30 HE
|
Medicenna Therapeutics Corp.
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2...
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09 avr. 2024 12h01 HE
|
Medicenna Therapeutics Corp.
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the...
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
04 avr. 2024 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
06 mars 2024 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
14 févr. 2024 07h30 HE
|
Medicenna Therapeutics Corp.
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint...
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
13 févr. 2024 07h00 HE
|
Medicenna Therapeutics Corp.
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11...
Medicenna Announces Appointment of New Auditor
12 janv. 2024 17h36 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
09 janv. 2024 07h00 HE
|
Medicenna Therapeutics Corp.
The ABILITY-1 Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11...
Medicenna Extends Period to Exercise Certain Warrants
21 déc. 2023 19h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company focused on the...
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
19 déc. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused...